Document 3051
 DOCN  M94A3051
 TI    Activated CD8-cells--a new surrogate marker?
 DT    9412
 AU    Hoffmann UJ; Mischo M; Reichelt D; Busch H; Zidek W; Medizinische
       Poliklinik, University of Munster, Germany.
 SO    Int Conf AIDS. 1994 Aug 7-12;10(1):165 (abstract no. PB0087). Unique
       Identifier : AIDSLINE ICA10/94369524
 AB    OBJECTIVE: To determine the usefullness of CD38+CD8+ and HLA-DR+CD8+
       cells for monitoring of antiretroviral therapy. METHODS: HIV infected
       patients who started or changed an antiretroviral therapy were
       controlled for lymphocyte subsets, beta 2-microglobulin, p24 antigen and
       antibodies, and immunoglobulins at baseline and after 1, 2, 3, and 6
       months. RESULTS: The expression of CD38+CD8+ and HLA-DR+CD8+ lymphoid
       phenotypic markers is increased after 1 month of zidovudine (ZDV)
       therapy with subsequent decrease. With didanosine (ddI) monotherapy only
       slight changes of these markers could be detected. Patients on
       combination therapy with ZDV and zalcitabine (ddC) showed an initial
       decrease of the number of CD38+CD8+ cells followed by an increase.
       Similar results were found for HLA-DR+CD8+ cells. CONCLUSIONS: The
       number of CD38+CD8+ and HLA-DR+CD8+ cells is modulated by antiretroviral
       therapy. The kind of modulation seems to be dependent on the choice of
       the nucleosid analogon.
 DE    Antigens, CD8/*BLOOD  Antigens, Differentiation/*BLOOD
       Didanosine/ADMINISTRATION & DOSAGE  Drug Therapy, Combination  Follow-Up
       Studies  Human  HIV Infections/DRUG THERAPY/*IMMUNOLOGY  HLA-DR
       Antigens/*BLOOD  Leukocyte Count/DRUG EFFECTS  Lymphocyte
       Transformation/DRUG EFFECTS/*IMMUNOLOGY  T-Lymphocyte Subsets/DRUG
       EFFECTS/*IMMUNOLOGY  Zalcitabine/ADMINISTRATION & DOSAGE
       Zidovudine/ADMINISTRATION & DOSAGE  MEETING ABSTRACT

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).